If you or a loved one is taking Tysabri, understanding the long-term risks—especially progressive multifocal leukoencephalopathy (PML)—is crucial. Recent studies continue to refine our knowledge of PML incidence and monitoring strategies, building on decades of pharmacovigilance data. This page reviews current research findings and what they mean for patients and healthcare providers.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Florida who have developed PML after Tysabri exposure, understanding the medical evidence linking the drug to this harm, the adequacy of risk warnings, and the legal time limits for filing a claim is essential. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, and healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs the normal immune response that controls JC virus reactivation. In immunocompromised patients, JC virus can infect oligodendrocytes, leading to demyelination and the characteristic clinical presentation of PML, which includes progressive neurological deficits such as weakness, visual changes, cognitive decline, and ataxia. Diagnosis is confirmed by MRI findings and detection of JC virus DNA in cerebrospinal fluid.
The adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. The boxed warning explicitly states that PML usually leads to death or severe disability and that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some plaintiffs have argued that these warnings were insufficient or that the risks were not adequately communicated to patients and prescribers before the drug's widespread use. The TOUCH Prescribing Program was established to manage the risk, requiring prescribers to evaluate patients at specified intervals and to report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML cases have continued to occur, and settlements have been reached in some cases to compensate affected patients.
For patients in Florida, the statute of limitations for filing a Tysabri-related PML lawsuit is typically governed by Florida's personal injury laws. In Florida, the statute of limitations for personal injury claims is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the limit is two years from the date of death. The timeline between Tysabri exposure and documented harm is critical: PML often develops after months to years of treatment, with the highest risk after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who were diagnosed with PML after discontinuing Tysabri should note that monitoring is required for at least six months after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and symptoms may appear during this period. Settlement considerations for affected patients include the severity of disability, medical expenses, lost income, and pain and suffering. Because PML often results in permanent neurological impairment, settlements may be substantial. However, patients must act within the applicable statute of limitations to preserve their right to compensation. It is advisable for individuals who have taken Tysabri and developed PML, or their families, to consult with a legal professional experienced in pharmaceutical litigation to assess their specific circumstances and ensure timely filing.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Florida, the statute of limitations for personal injury claims is generally four years from the date the injury was discovered or should have been discovered. For wrongful death claims, the limit is two years from the date of death. Because PML symptoms may appear months to years after starting Tysabri, it is crucial to act promptly to preserve your right to compensation.
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the Tysabri prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.